TY - JOUR T1 - Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA3916 VL - 58 IS - suppl 65 SP - PA3916 AU - Valentina Agnese Ferraro AU - Amelia Licari AU - Alessandro Volpini AU - Grazia Fenu AU - Manuela Seminara AU - Franca Rusconi Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA3916.abstract N2 - Few data are available on clinical and laboratory history after discontinuation of Omalizumab in children with severe asthma.Aim: to evaluate children with severe allergic asthma after Omalizumab withdrawal.Methods: this is a longitudinal cohort study in children with severe asthma treated for at least 2 years with Omalizumab, that was discontinued after a good clinical response. We analyzed at the time of withdrawal (T0), and at 3 (T1), 6 (T2), and 12 months (T3) after discontinuation the followings: asthma control (questionnaires), spirometry (GLI reference values), quality of life (PAQLQ), and markers of Th2-inflammation (FeNO, blood eosinophils, total IgE).Results: we evaluated so far 14 children followed up at least to T2. Ten of 14 were males; median age was 15 years; duration of Omalizumab treatment 2-6 years (median: 3). At T2, all showed good symptoms control (median GINA score remained 0), even if 2 experienced asthmatic exacerbations (AE) (one child 1 AE and the other 2 AE). Only the child with 2 AE required an increase in maintenance therapy. FEV1 did not change significantly (median: T0 92% pred and T2 90,6 %pred; z-score T0: -0,64 and T2: - 0,80; p=0,18). Overall, quality of life was good (median PAQLQ at T0: 6,9; at T3: 7.0; p=0,28). 10/10 patients followed up to T3 maintained good control of the disease and only 1 had an AE.Conclusions: with the limit imposed by the number of patients enrolled so far, these preliminary data show that a number of patients have good asthma control after discontinuation of Omalizumab after 6 months, and some also after 12 months. Recruitment and follow-up are ongoing.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3916.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -